Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 23 EP applications Michael Wiessner has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after February 17, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12700701

4-TOLYL-ETHYNYL-OCTAHYDRO-INDOLE-1-ESTER DERIVATIVES

IPC classification:
A61K 31/403, A61P 25/00, C07D 209/26
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12700262

IMMUNOSUPPRESSANT FORMULATIONS

IPC classification:
A61K 9/20, A61K 31/397
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP11757513

USE OF 1H-QUINAZOLINE- 2, 4 -DIONES FOR USE IN THE PREVENTION OR TREATMENT PHOTOSENSITIVE EPILEPSY

IPC classification:
A61K 31/517, A61P 25/08, C07D 239/96, C07D 403/04, C07D 405/04
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12772986

DOSAGE REGIMEN FOR AN S1P RECEPTOR MODULATOR OR AGONIST

IPC classification:
A61K 31/132, A61K 31/137, A61K 31/196, A61K 31/397, A61P 37/00
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12701342

USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS

IPC classification:
A61K 31/00, A61P 25/16
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13702472

PROCESS FOR PREPARING N-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-ACETIMIDIC ACID ETHYL ESTER

IPC classification:
C07C 22/08, C07C 33/34, C07C 47/55, C07C 251/48, C07D 205/04
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13173514

Immunosuppressant Compounds and Compositions

IPC classification:
A61K 31/4725, A61P 35/00, C07D 261/20, C07D 333/58, C07D 409/06, C07D 471/04, C07D 473/00, C07D 513/04
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11802917

4- (HETERO) ARYL - ETHYNYL - OCTAHYDRO - INDOLE - 1 - CARBOXYLIC ACID ESTERS

IPC classification:
A61K 31/404, A61K 31/427, A61K 31/4439, A61P 1/00, A61P 13/02, A61P 25/00, C07D 209/08, C07D 401/06, C07D 417/06
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11729624

CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS

IPC classification:
A61K 31/444, C07D 407/04, C07D 407/14, C07D 417/14, C07D 491/04
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11719840

2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES

IPC classification:
A61K 31/517, A61P 25/08, C07D 403/04, C07D 405/04
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP15173766

COMPOSITIONS COMPRISING SPHINGOSINE I PHOSPHATE (SIP) RECEPTOR MODULATORS

IPC classification:
A61K 9/00, A61K 9/20, A61K 9/70, A61K 31/137
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15177166

S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS

IPC classification:
A61K 31/137, A61K 31/397, A61P 37/06
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15177158

PAEDIATRIC COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS

IPC classification:
A61K 31/137, A61P 37/00
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15185231

AMINOALKANOL DERIVATIVES

IPC classification:
A61K 31/135, A61P 37/00, C07C 215/28, C07C 233/22
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15186346

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

IPC classification:
A61K 31/137, A61P 11/06, A61P 37/06, G06F 19/00
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15188591

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

IPC classification:
A61K 31/137, A61P 11/06, A61P 37/06, G06F 19/00
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP13154157

Pim kinase inhibitors and methods of their use

IPC classification:
A61K 31/4439, A61P 35/00, C07D 417/14
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13177190

HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3 -TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID FOR USE IN THE TREATMENT OF LYMPHOCYTE MEDIATED DISEASES

IPC classification:
A61K 31/397, A61P 35/00, A61P 37/00, C07D 205/04
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
PATENT GRANTED
EP15735733

IMMUNOSUPPRESSANT FORMULATION

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/28, A61K 31/397
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15717256

S1P MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN

IPC classification:
A61K 9/20, A61K 31/397
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16176665

FORMULATIONS COMPRISING 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/48, A61K 31/137, A61K 31/661, A61K 47/40, A61P 37/06
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
Request for examination was made
EP15784974

COMBINATIONS COMPRISING SIPONIMOD AND LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS

IPC classification:
A61K 31/397, A61K 31/4704, A61P 37/00
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis AG
Status:
Request for examination was made
EP16202251

IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS

IPC classification:
A61K 31/135, A61P 29/00, C07C 251/48, C07C 251/52, C07C 251/54, C07D 205/04, C07D 207/16, C07D 211/60, C07D 213/30, C07D 213/53, C07D 213/61, C07D 217/04, C07D 295/06, C07D 307/10, C07D 307/12, C07D 307/52, C07D 333/12, C07D 333/16, C07D 333/22
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
The application has been published

Please Sign in to use this feature